A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs IPI 549 (Primary) ; Nivolumab
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 03 Aug 2017 According to an Infinity Pharmaceuticals media release, dose escalation evaluating IPI-549 in combination with Opdivo is ongoing, and the company expects to initiate the combination expansion component of the study in the second half of 2017.
    • 03 Aug 2017 According to an Infinity Pharmaceuticals media release, patient enrollment in the monotherapy dose-escalation component of the study has been completed and the monotherapy expansion component of the study is now open for enrollment and will evaluate the safety and activity of IPI-549 dosed at 60 QD in approximately 25 patients.
    • 14 Jun 2017 According to an Infinity Pharmaceuticals media release, results from this trial will be presented at the 2017 Precision: Lung Cancer Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top